AMS Newsletter | 29 November 2023

Senate Inquiry into issues relating to menopause and perimenopause

You may be aware that on 6 November 2023, the Senate referred the above matter to the Senate Community Affairs References Committee for inquiry and report by 10 September 2024. The terms of reference are available online and are outlined below:

Issues related to menopause and perimenopause, with particular reference to:

1. the economic consequences of menopause and perimenopause, including but not limited to, reduced workforce participation, productivity and retirement planning;
2. the physical health impacts, including menopausal and perimenopausal symptoms, associated medical conditions such as menorrhagia, and access to healthcare services;
3. the mental and emotional well-being of individuals experiencing menopause and perimenopause, considering issues like mental health, self-esteem, and social support;
4. the impact of menopause and perimenopause on caregiving responsibilities, family dynamics, and relationships;
5. the cultural and societal factors influencing perceptions and attitudes toward menopause and perimenopause, including specifically considering culturally and linguistically diverse communities and women’s business in First Nations communities;
6. the level of awareness amongst medical professionals and patients of the symptoms of menopause and perimenopause and the treatments, including the affordability and availability of treatments;
7. the level of awareness amongst employers and workers of the symptoms of menopause and perimenopause, and the awareness, availability and usage of workplace supports;
8. existing Commonwealth, state and territory government policies, programs, and healthcare initiatives addressing menopause and perimenopause;
9. how other jurisdictions support individuals experiencing menopause and perimenopause from a health and workplace policy perspective; and any other related matter.

The AMS Board plans to provide a submission on behalf of AMS members.

Submissions can be made here and are due by 16 February 2024.

Menopausal Hormone Therapy (MHT) Patch discontinuation and shortages

AMS is pleased to present an updated version of the Tibolone as menopausal hormone therapy with thanks to Dr Ashley Makepeace. Tibolone is a synthetic steroid hormone. Its metabolites have oestrogenic, progestogenic and androgenic properties. Indications are for the management of oestrogen deficiency symptoms and for the prevention of bone loss at the time of menopause.

Dr Christina Jang
Coordinator, AMS Information and Fact Sheets

IMS World Congress on Menopause in Melbourne 2024

Health Professionals - join AMS for Members-only content 

IMS Live 21 November 2023: During the postmenopausal stage women often display adverse lipid profiles; however, evidence is insufficient regarding the association between lipids and reproductive aging in Korean women. Bearing this in mind, Park et al. [1] aimed to characterize lipid changes in relation to the timing of menopause in 1,436 Korean mid-aged (premenopausal) women who had a natural menopause during the follow-up period (median = 15.76 years) from the Korean Genome and Epidemiology Study (KoGES) Ansan and Anseong cohort. Lipid levels were measured every 2 years, and the magnitudes of annual lipid changes and differences in the changes by premenopausal body mass index were estimated using piecewise linear mixed-effects models...

Sexual Health During and After Cancer - video
Dr Bober discusses changes in sexual health during and after cancer. She reviews that sexual recovery after cancer is a process and an important part of a patient’s quality of life. She encourages healthcare professionals to discuss sexual concerns with their patients and direct them to the best resources available.

Brain Teasers: Challenges in the cranium - webinar archive
Moderator: Professor Pauline Maki |Speakers: Professor Anne MacGregor: ‘Menopause and Migraine’ | Doctor Riley Bove: ‘Hormone Therapy and Multiple Sclerosis: Help or hindrance?’

IMS Newsletter November 2023
AMS is an affiliate of IMS See latest available copy.

European Menopause and Andropause Society (EMAS) Newsletter
AMS is an affiliate of EMAS. See a copy of the November newsletter.